- Drug Class
- Neuraminidase Inhibitor
- Mechanism of Action (MOA)
- Inhibits influenza neuraminidase → prevents release of new virions from infected cells.
- Clinical Notes
- Influenza A & B — most benefit started within 48 h of symptom onset (shortens course ~1 day). Neuropsychiatric events reported.
Sources
Reviewed June 2026- FDA label — FDA / DailyMed
Checked against the guideline or standard reference the exam keys to. If it has moved, use Report an error below.
All pharmacology